Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Osimertinib activates a TGF-β2–dependent secretory program that drives lung adenocarcinoma progression
Madhurima Ghosh, Chao Wu, Abhishek Kumar, Monique Nilsson, John V. Heymach, Weina Zhao, Jiang Yu, Xin Liu, Na Ding, Shike Wang, Guan-Yu Xiao, Angelo Chen, Kate Grimley, William K. Russell, Chad J. Creighton, Xiaochao Tan, Jonathan M. Kurie
Madhurima Ghosh, Chao Wu, Abhishek Kumar, Monique Nilsson, John V. Heymach, Weina Zhao, Jiang Yu, Xin Liu, Na Ding, Shike Wang, Guan-Yu Xiao, Angelo Chen, Kate Grimley, William K. Russell, Chad J. Creighton, Xiaochao Tan, Jonathan M. Kurie
View: Text | PDF
Research Article Cell biology Clinical Research Oncology

Osimertinib activates a TGF-β2–dependent secretory program that drives lung adenocarcinoma progression

  • Text
  • PDF
Abstract

EGFR-mutant lung adenocarcinomas (LUADs) that are vulnerable to the EGFR antagonist osimertinib (Osi) eventually relapse, owing in part to the emergence of drug-tolerant persister (DTP) cells that arise through epigenetic mechanisms. Intratumoral DTP cells can herald a worse clinical outcome, but the way in which DTP cells influence LUAD progression remains unclear. Osi-resistant (OR) cells exhibit typical DTP cell features, including a propensity to undergo senescence and epithelial-mesenchymal transition (EMT), which can activate heightened secretory states. Therefore, we postulated that OR cells influence LUAD progression through paracrine mechanisms. To test this hypothesis, we utilized congenic pairs of EGFR-mutant LUAD cell lines in which drug-naive (DN) cells were rendered OR by chronic exposure to escalating doses of Osi. Cocultured in vitro or coinjected into mice, paracrine signals from OR cells enhanced the growth and metastatic properties of DN cells. EMT and senescence activated nonoverlapping secretomes, and OR cells governed DN cells by undergoing EMT but not senescence. Mechanistically, Osi rapidly increased TGF-β2 levels to initiate EMT, which triggered a Golgi remodeling process that accelerated the biogenesis and anterograde trafficking of secretory vesicles. The protumorigenic activity of OR cells was diminished by depletion of EMT-dependent secreted proteins or the EMT-activating transcription factor ZEB1. These findings identify paracrine mechanisms by which OR cells drive LUAD progression.

Authors

Madhurima Ghosh, Chao Wu, Abhishek Kumar, Monique Nilsson, John V. Heymach, Weina Zhao, Jiang Yu, Xin Liu, Na Ding, Shike Wang, Guan-Yu Xiao, Angelo Chen, Kate Grimley, William K. Russell, Chad J. Creighton, Xiaochao Tan, Jonathan M. Kurie

×

Figure 6

EMT drives Golgi and secretory dynamics in OR cells.

Options: View larger image (or click on image) Download as PowerPoint
EMT drives Golgi and secretory dynamics in OR cells.
(A and B) Quantitat...
(A and B) Quantitative PCR analysis of mRNA levels in HCC827 cells (OR and DN). Relative levels of EMT-activating transcription factors (ZEB1, SNA1, SNAI2), and mesenchymal marker VIM (A). Relative levels of epithelial polarity complex components (CDH1, PATJ, CRB3, and CLDN3) are indicative of EMT in OR cells (B). (C) WB confirmation of siRNA-mediated target gene depletion in HCC827 OR cells. β-Actin served as loading control. (D) Scatter plot of Golgi areas per siRNA-transfected cell (dot). Values normalized to nucleus area. (E) Scatter plot of Golgi element numbers per cell (dot). (F) Scatter plot of intensity recovery (%) after photobleaching (n = 10 cells per group). (G) Quantification of Rab6A+ vesicles per cell (dot). Vesicles identified based on GFP-tagged Rab6A reporter activity. (H) Ratio of surface-to-total VSV-G per cell (dot) infected with adenovirus expressing EGFP-VSV-G and imaged 30 minutes after transfer to 32°C. (I) WB analysis of L1CAM in CM and whole-cell lysate samples. (J) WB confirmation of shRNA-mediated target gene depletion in H1975 OR cells. β-Actin served as loading control. (K and L) DN cells were injected in combination with cells described in J (10:1 ratio) into nu/nu mice. At necropsy, each mouse (dot) was scored based on primary lung tumor numbers (K) and mediastinal lymph node and contralateral lung tumor metastases (L). Data are the mean ± SD from a single experiment incorporating biological replicate samples (n = 3, unless otherwise indicated) and are representative of at least 2 independent experiments. Two-tailed Student’s t test (A and B). One-way ANOVA with Dunnet’s post hoc test (D, E, G, H, K, and L). Two-way ANOVA with Dunnet’s post hoc test (F).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts